<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00093561</url>
  </required_header>
  <id_info>
    <org_study_id>UIC-2004-0040</org_study_id>
    <secondary_id>CDR0000389223</secondary_id>
    <nct_id>NCT00093561</nct_id>
  </id_info>
  <brief_title>Lycopene in Preventing Prostate Cancer in Healthy Participants</brief_title>
  <official_title>Phase I Single Dose Pharmacokinetic Study of the Dietary Supplement Lycopene Delivered in Capsule Form to Healthy Male Volunteers Between 18 and 45 Years of Age</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Illinois at Chicago</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      RATIONALE: Chemoprevention therapy is the use of certain substances to try to prevent the&#xD;
      development or recurrence of cancer. The dietary supplement lycopene may prevent the&#xD;
      development of prostate cancer.&#xD;
&#xD;
      PURPOSE: This phase I trial is studying the side effects and best dose of lycopene in&#xD;
      preventing prostate cancer in healthy participants.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Determine the toxicity and safety of lycopene supplementation as chemoprevention for&#xD;
           prostate cancer in healthy participants.&#xD;
&#xD;
        -  Determine the pharmacokinetics of this agent in these participants.&#xD;
&#xD;
        -  Determine the dose range of this agent in these participants.&#xD;
&#xD;
      OUTLINE: This is a dose-escalation study.&#xD;
&#xD;
      Participants ingest a single-dose of oral lycopene over a maximum of 15 minutes on day 1.&#xD;
&#xD;
      Cohorts of 5 participants receive escalating doses of lycopene until the maximum tolerated&#xD;
      dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 5&#xD;
      participants experience dose-limiting toxicity.&#xD;
&#xD;
      Participants are evaluated periodically for 28 days.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 25 participants will be accrued for this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2004</start_date>
  <completion_date type="Actual">February 2006</completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Prevention</primary_purpose>
  </study_design_info>
  <primary_outcome>
    <measure>Toxicity by blood chemistries and patient histories at 4 weeks after treatment</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics by blood lycopene concentrations at 4 weeks after treatment</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Define dose range by blood lycopene concentrations at 4 weeks after treatment</measure>
  </secondary_outcome>
  <condition>Prostate Cancer</condition>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>lycopene</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Healthy participants in good medical condition&#xD;
&#xD;
               -  No chronic medical conditions&#xD;
&#xD;
               -  No regular use of prescription medications&#xD;
&#xD;
               -  No evidence of psychiatric disorder&#xD;
&#xD;
               -  Non-smoker&#xD;
&#xD;
                    -  Former smokers allowed provided they have not smoked within the past 3&#xD;
                       months&#xD;
&#xD;
               -  No history of alcohol abuse&#xD;
&#xD;
          -  Serum lycopene concentration &lt; 700 nM&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age&#xD;
&#xD;
          -  18 to 45&#xD;
&#xD;
        Performance status&#xD;
&#xD;
          -  Karnofsky 100%&#xD;
&#xD;
        Life expectancy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hematopoietic&#xD;
&#xD;
          -  Hemoglobin ≥ 13.0 g/dL&#xD;
&#xD;
          -  WBC ≥ 4,000/mm^3&#xD;
&#xD;
          -  Platelet count 150,000-400,000/mm^3&#xD;
&#xD;
        Hepatic&#xD;
&#xD;
          -  AST and ALT ≤ 75 U/L&#xD;
&#xD;
          -  Bilirubin ≤ 2.0 mg/dL&#xD;
&#xD;
          -  No liver disease&#xD;
&#xD;
        Renal&#xD;
&#xD;
          -  Creatinine ≤ 1.5 mg/dL&#xD;
&#xD;
          -  No renal disease&#xD;
&#xD;
        Cardiovascular&#xD;
&#xD;
          -  No cardiovascular disease&#xD;
&#xD;
          -  No abnormal EKG&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  Within 15% of ideal body weight&#xD;
&#xD;
          -  No history of gastrointestinal malabsorption or other condition that would preclude&#xD;
             drug absorption&#xD;
&#xD;
          -  No alcohol consumption within the past 72 hours&#xD;
&#xD;
          -  No allergy to tomato-based products&#xD;
&#xD;
          -  No history of cancer&#xD;
&#xD;
          -  No diabetes mellitus&#xD;
&#xD;
          -  No other illness that would preclude study participation&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Chemotherapy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Endocrine therapy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Radiotherapy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Surgery&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  At least 4 weeks since prior experimental drugs&#xD;
&#xD;
          -  More than 14 days since prior prescription drugs&#xD;
&#xD;
          -  No concurrent participation in another experimental trial&#xD;
&#xD;
          -  No concurrent prescription drugs&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Keith A. Rodvold</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Illinois at Chicago</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Illinois at Chicago Cancer Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2006</verification_date>
  <study_first_submitted>October 6, 2004</study_first_submitted>
  <study_first_submitted_qc>October 7, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 8, 2004</study_first_posted>
  <last_update_submitted>June 25, 2013</last_update_submitted>
  <last_update_submitted_qc>June 25, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 26, 2013</last_update_posted>
  <keyword>prostate cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lycopene</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

